Identification of a Low Affinity Mannose 6-phosphate-binding Site in Domain 5 of the Cation-independent Mannose 6-phosphate Receptor
Overview
Affiliations
The 300-kDa cation-independent mannose 6-phosphate receptor (CI-MPR) and the 46-kDa cation-dependent MPR (CD-MPR) are type I integral membrane glycoproteins that play a critical role in the intracellular delivery of newly synthesized mannose 6-phosphate (Man-6-P)-containing acid hydrolases to the lysosome. The extracytoplasmic region of the CI-MPR contains 15 contiguous domains, and the two high affinity ( approximately 1 nm) Man-6-P-binding sites have been mapped to domains 1-3 and 9, with essential residues localized to domains 3 and 9. Domain 5 of the CI-MPR exhibits significant sequence homology to domains 3 and 9 as well as to the CD-MPR. A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket. To determine whether domain 5 harbors a carbohydrate-binding site, a construct that encodes domain 5 alone (Dom5His) was expressed in Pichia pastoris. Microarray analysis using 30 different oligosaccharides demonstrated that Dom5His bound specifically to a Man-6-P-containing oligosaccharide (pentamannosyl 6-phosphate). Frontal affinity chromatography showed that the affinity of Dom5His for Man-6-P was approximately 300-fold lower (K(i) = 5.3 mm) than that observed for domains 1-3 and 9. The interaction affinity for the lysosomal enzyme beta-glucuronidase was also much lower (K(d) = 54 microm) as determined by surface plasmon resonance analysis. Taken together, these results demonstrate that the CI-MPR contains a third Man-6-P recognition site that is located in domain 5 and that exhibits lower affinity than the carbohydrate-binding sites present in domains 1-3 and 9.
Hirata T, Kizuka Y Adv Exp Med Biol. 2021; 1325:3-24.
PMID: 34495528 DOI: 10.1007/978-3-030-70115-4_1.
Broqueza J, Prabaharan C, Andrahennadi S, Allen K, Dickinson R, MacDonald-Dickinson V Cancers (Basel). 2021; 13(9).
PMID: 34064450 PMC: 8124616. DOI: 10.3390/cancers13092208.
Kanzaki M, Tsukimura T, Chiba Y, Sakuraba H, Togawa T Mol Genet Metab Rep. 2020; 25:100639.
PMID: 32884906 PMC: 7451420. DOI: 10.1016/j.ymgmr.2020.100639.
Torrente Y, Bella P, Tripodi L, Villa C, Farini A Cells. 2020; 9(2).
PMID: 32075092 PMC: 7072799. DOI: 10.3390/cells9020441.
Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy.
Bella P, Farini A, Banfi S, Parolini D, Tonna N, Meregalli M EMBO Mol Med. 2019; 12(1):e11019.
PMID: 31793167 PMC: 6949491. DOI: 10.15252/emmm.201911019.